In Segment C, participants will obtain ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment right until illness progression or the participants are unable to tolerate the study drugs. Achievable new strategies for your prognosis and treatment of AML. (A) The identification https://howdoesabbv-744workincanc57912.bligblogging.com/32601615/the-best-side-of-abbv-744-clinical-trial-phase-2-data